Targeting EGFR using traditional targeted therapies, such as monoclonal antibodies or tyrosine kinase inhibitors (TKIs), as radiosensitizers have gained moderate success in non-small-cell lung cancer (NSCLC), but failed in GBM and HNSCC to improve OS rates (108, 109). This evidence concerns the gene EGFR and glioblastoma.